Saltar al contenido
Merck

SRE0024

Glyceraldehyde-3-phosphate dehydrogenase human

recombinant, expressed in Escherichia coli

Sinónimos:

D-Glyceraldehyde-3-phosphate: NAD+ oxidoreductase (phosphorylating), GAPDH, Triosephosphate dehydrogenase

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño


Acerca de este artículo

UNSPSC Code:
12352204
NACRES:
NA.54
Número CE:
1.2.1.12
Specific activity:
≥80 units/mg protein
Recombinant:
expressed in E. coli
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

recombinant

expressed in E. coli

specific activity

≥80 units/mg protein

storage temp.

−20°C

Quality Level

Categorías relacionadas

General description

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) localizes to the cytoplasm but can be translocated to the nucleus depending on cellular conditions. It is a tetramer containing identical chains. The gene encoding GAPDH is localized on human chromosome 12p13.

Application

Human glyceraldehyde-3-phosphate dehydrogenase has been used as a positive control for hydrogen sulfide treatment to detect sulfhydration of protein targets.

Biochem/physiol Actions

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) catalyzes the reversible oxidative phosphorylation of glyceraldehyde-phosphate, which is a critical energy-yielding step in carbohydrate metabolism. It binds to several proteins including actin, tubulin, amyloid precursor, polyglutamine peptides, DRPLA (dentatorubral-pallidoluysian atrophy) and huntingtin. Phosphorylated GAPDH associates with cytoskeletal elements and controls microtubule dynamics in the early secretory pathway. GAPDH is also a component of the functional GAIT (interferon-?-activated inhibitor of translation) mRNP (messenger ribonucleoprotein). GAPDH expression is dysregulated during melanoma progression.

Physical form

This product is recombinant, human GAPDH expressed in E. coli with an N-terminal histidine tag and has a predicted molecular mass of 37,984 Da. The product is lyophilized from a buffered solution with stabilizers.

Other Notes

Alternative number: CAS Number 9001-50-7
One unit will reduce 1.0 μmole of 3-phosphoglycerate to D-glyceraldehyde 3-phosphate per minute in a coupled system with 3-phosphoglyceric phosphokinase (3-PGK) at pH 7.6 at 25 °C

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Eye Irrit. 2

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Noncanonical function of glutamyl-prolyl-tRNA synthetase: gene-specific silencing of translation.
Sampath P, et al.
Cell, 119(2), 195-208 (2004)
Deregulation of glyceraldehyde-3-phosphate dehydrogenase expression during tumor progression of human cutaneous melanoma.
Ramos D, et al.
Anticancer Research, 35(1), 439-444 (2015)
Hydrogen sulfide inhibits Kir2 and Kir3 channels by decreasing sensitivity to the phospholipid PIP2.
Ha J, et al.
The Journal of Biological Chemistry, RA117-RA117 (2018)
Joana Alves et al.
PloS one, 10(12), e0144196-e0144196 (2015-12-18)
Group B Streptococcus (GBS), a commensal organism, can turn into a life-threatening pathogen in neonates and elderly, or in adults with severe underlying diseases such as diabetes. We developed a vaccine targeting the GBS glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a glycolytic enzyme
Gennaro Napolitano et al.
EMBO molecular medicine, 7(2), 158-174 (2015-01-15)
Metabolite accumulation in lysosomal storage disorders (LSDs) results in impaired cell function and multi-systemic disease. Although substrate reduction and lysosomal overload-decreasing therapies can ameliorate disease progression, the significance of lysosomal overload-independent mechanisms in the development of cellular dysfunction is unknown

Contenido relacionado

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico